Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

About this update from Rigel Pharmaceuticals, Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026","length":264,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 Outlook: Rigel anticipates full-year total revenues of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year ","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call and webcast scheduled today at 4:30 p.m. Eastern Time","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1011,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended December 31, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress.","length":454,"tagName":"p"},{"type":"text","content":""I am proud to highlight Rigel's tremendous progress during 2025 across each of the key value drivers of our business. We delivered record net product sales, total revenues and net income while making meaningful advances in our Phase 1b study of R289 in lower-risk MDS," said Raul Rodriguez, Rigel's president and CEO. "These 2025 accomplis...

More updates from Rigel Pharmaceuticals, Inc.